Mode of Action and Human Relevance Assessment of Male CD-1 Mouse Renal Adenocarcinoma Associated With Lifetime Exposure to Empagliflozin - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35393688/
Inhibition of sodium-glucose cotransporter-2 (SGLT2) has been shown to be a safe and efficacious approach to support managing Type 2 diabetes. In the 2-year carcinogenicity study with the SGLT2 inhibitor...
Conclusions and Implications: Considering that empagliflozin is not genotoxic in the standard battery of genotoxicity tests, and not all five key events are present in the context of female mice, rats or humans, nor for other osmotic diuretics or other SGLT2 inhibitors, the observed male mouse renal tumors are not considered relevant to humans.
Share
Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors
Source : https://www.cjhp-online.ca/index.php/cjhp/article/view/3066
Michael Fralick Sinai Health System, University of Toronto Diana Martins Unity Health Toronto Mina Tadrous Women's College Research Institute, Women's College Hospital; ICES; University of Toronto Tara Gomes Unity Health...
Conclusions: The cardiovascular outcome trials appeared to have an important impact on the dispensing of SGLT2 inhibitors in Canada.
Share
Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35391843/
doi: 10.3389/fcvm.2022.854230. 1 Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. 2 Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital,...
Conclusion: SGLT2 inhibition lowers daytime and nighttime ambulatory systolic and diastolic BP in normotensive non-diabetic subjects. Twenty-four jour changes are pronounced and comparable to those described in diabetic or hypertensive subjects. Baseline ambulatory BP was the only identified determinant of systolic and diastolic BP response....
Share
Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35397165/
doi: 10.1210/clinem/dgac210. Online ahead of print. 1 Department of Endocrinology, Henan Provincial Key Medicine Laboratory of Intestinal Microecology and Diabetes, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou,...
Conclusions: Empagliflozin may be a superior initial therapy for patients with T2DM at risk of CVDs; its cardiovascular benefits may be associated with shifts in gut microbiota and plasma metabolites.
Share
SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35329796/
The incidence of both diabetes mellitus type 2 and heart failure is rapidly growing, and the diseases often coexist. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new antidiabetic drug class...
Conclusions: The expected paradigm shift in treatment strategies was reflected in the most recent 2021 guidelines published by the European Society of Cardiology, recommending dapagliflozin and empagliflozin as first-line treatment for heart failure patients with reduced ejection fraction. Moreover, the recent results of the EMPEROR-Preserved...
Share